share_log

10-K/A: Annual report (Amendment)

SEC ·  Apr 30 04:21

Summary by Moomoo AI

180 Life Sciences Corp. (180 Life Sciences) has filed an amended annual report for the fiscal year ended December 31, 2023. The report includes the dismissal of Marcum LLP as the independent registered public accounting firm and the engagement of M&K CPA’s, PLLC for the fiscal year 2024. The company has also entered into indemnification agreements with directors and officers, and has established a policy for the Audit Committee to review and approve any related party transactions. Legal actions involving former CEO Dr. Marlene Krauss and Tyche Capital LLC are ongoing, with the company vigorously defending its position. The company has also initiated legal action against Ronald Bauer and Samantha Bauer for misappropriated funds and stock shares. The Board has determined that new appointees Blair Jordan, Omar Jiminez, and Ryan Smith are independent directors. The report also details the compensation of directors and executive officers, including equity compensation plans and related fees for services rendered during the fiscal year.
180 Life Sciences Corp. (180 Life Sciences) has filed an amended annual report for the fiscal year ended December 31, 2023. The report includes the dismissal of Marcum LLP as the independent registered public accounting firm and the engagement of M&K CPA’s, PLLC for the fiscal year 2024. The company has also entered into indemnification agreements with directors and officers, and has established a policy for the Audit Committee to review and approve any related party transactions. Legal actions involving former CEO Dr. Marlene Krauss and Tyche Capital LLC are ongoing, with the company vigorously defending its position. The company has also initiated legal action against Ronald Bauer and Samantha Bauer for misappropriated funds and stock shares. The Board has determined that new appointees Blair Jordan, Omar Jiminez, and Ryan Smith are independent directors. The report also details the compensation of directors and executive officers, including equity compensation plans and related fees for services rendered during the fiscal year.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more